secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outset Medical, Inc. (OM)
CIK:        0001484612
Form:       8-K
Filed at:   2026-02-11T23:59:59+00:00
Accession:  0001193125-26-046588
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outset Medical reports FY2025 revenue $119.5M (+5% YoY); provides 2026 guidance $125-130M
--------------------------------------------------------------------------------

- Q4 revenue $28.9M; full year 2025 revenue $119.5M (+5% YoY); recurring revenue $88.7M (+6%).
- Gross margin expanded to 42.4% in Q4 (non-GAAP 42.9%), up ~600 bps vs Q4 2024.
- Net loss narrowed to $81.7M in 2025 from $128M in 2024; cash $173M; ops cash burn $46M vs $116M.
- Received FDA clearance for next-generation Tablo platform; launch expected in Q2 2026.
- FY2026 guidance: revenue $125M-$130M (+5-9% YoY); non-GAAP gross margin low to mid-40%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484612/000119312526046588/0001193125-26-046588-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484612/000119312526046588/om-20260211.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-046588

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer